SpyGlass Pharma Inc SGP
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
SpyGlass Pharma to Participate in Upcoming Investor Conferences
SpyGlass Pharma Announces Positive 4-Year Data From First-in-Human Trial of Its Innovative BIM-IOL System
SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion Capability
SpyGlass Pharma to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $30.78
- Day Range
- $29.07–31.73
- 52-Week Range
- $17.06–39.92
- Bid/Ask
- $18.10 / $49.44
- Shares Outstanding
- 33.46M
- Market Cap
- $1.02B
- Volume/Avg
- 108,910 / 112,859
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
SpyGlass Pharma Inc is a late-stage biopharmaceutical company focused on transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company is developing two programs: the BIM-IOL System, which is intended for use during cataract surgery to deliver glaucoma treatment, and the BIM-DRS, which is designed for glaucoma patients who are not undergoing cataract surgery.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- —
- Total Number of Employees
- 65
Valuation
Metric | SGP |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.84 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | SGP |
|---|---|
Quick Ratio | 15.13 |
Current Ratio | 15.24 |
Interest Coverage | — |
Quick Ratio
SGP
Profitability
Metric | SGP |
|---|---|
Return on Assets (Normalized) | −32.70% |
Return on Equity (Normalized) | −62.64% |
Return on Invested Capital (Normalized) | −67.96% |
Return on Assets
SGP
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|@q@@#vF | LOCK|v?H<< | $131B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|L&$#kz | LOCK|vJ$^ | $95B | |||
| Moderna Inc MRNA | LOCK|x>!C#& | LOCK|!& | $79B | |||
| argenx SE ADR ARGX | LOCK|#bpB?%> | LOCK|^<> | $59B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|!w<&<!> | LOCK|@%Y | $45B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|$?#QnMs | LOCK|>rg< | $30B | |||
| Incyte Corp INCY | LOCK|xBJVQJS | LOCK|Nh@ | $23B | |||
| BioNTech SE ADR BNTX | LOCK|X&^b@lq | LOCK|@Z@ | $20B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|t<FjPV | LOCK|KV>? | $19B | |||
| BridgeBio Pharma Inc BBIO | LOCK|vdd<pG% | LOCK|x? | $15B |